Literature DB >> 23530077

Photochemical inactivation of chikungunya virus in human apheresis platelet components by amotosalen and UVA light.

Konstantin A Tsetsarkin1, Adam Sampson-Johannes, Lynette Sawyer, John Kinsey, Stephen Higgs, Dana L Vanlandingham.   

Abstract

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that recently re-emerged in Africa and rapidly spread into countries of the Indian Ocean basin and South-East Asia. The mean viremic blood donation risk for CHIKV on La Réunion reached 1.5% at the height of the 2005-2006 outbreaks, highlighting the need for development of safety measures to prevent transfusion-transmitted infections. We describe successful inactivation of CHIKV in human platelets and plasma using photochemical treatment with amotosalen and long wavelength UVA illumination. Platelet components in additive solution and plasma units were inoculated with two different strains of high titer CHIKV stock (6.0-8.0 logs/mL), and then treated with amotosalen and exposure to 1.0-3.0 J/cm² UVA. Based on in vitro assays of infectious virus pre- and post-treatment to identify endpoint dilutions where virus was not detectable, mean viral titers could effectively be reduced by > 6.4 ± 0.6 log₁₀ TCID₅₀/mL in platelets and ≥ 7.6 ± 1.4 logs in plasma, indicating this treatment has the capacity to prevent CHIKV transmission in human blood components collected from infected donors in or traveling from areas of CHIKV transmission.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23530077      PMCID: PMC3752818          DOI: 10.4269/ajtmh.12-0603

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  61 in total

1.  Stabilization of chikungunya virus infectivity by human blood platelets.

Authors:  R P Larke; E F Wheelock
Journal:  J Infect Dis       Date:  1970-12       Impact factor: 5.226

Review 2.  Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma.

Authors:  S Wollowitz
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

3.  Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.

Authors:  Dick van Rhenen; Hans Gulliksson; Jean-Pierre Cazenave; Derwood Pamphilon; Per Ljungman; Harald Klüter; Hans Vermeij; Mies Kappers-Klunne; Georgine de Greef; Michel Laforet; Bruno Lioure; Kathryn Davis; Stephane Marblie; Veronique Mayaudon; Jocelyne Flament; Maureen Conlan; Lily Lin; Peyton Metzel; Don Buchholz; Laurence Corash
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

4.  Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.

Authors:  Lily Lin; Roberta Dikeman; Barbara Molini; Sheila A Lukehart; Robert Lane; Kent Dupuis; Peyton Metzel; Laurence Corash
Journal:  Transfusion       Date:  2004-10       Impact factor: 3.157

5.  Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

Authors:  Jeffrey McCullough; David H Vesole; Richard J Benjamin; Sherrill J Slichter; Alvaro Pineda; Edward Snyder; Edward A Stadtmauer; Ileana Lopez-Plaza; Steven Coutre; Ronald G Strauss; Lawrence T Goodnough; Joy L Fridey; Thomas Raife; Ritchard Cable; Scott Murphy; Frank Howard; Kathryn Davis; Jin-Sying Lin; Peyton Metzel; Laurence Corash; Antonis Koutsoukos; Lily Lin; Donald H Buchholz; Maureen G Conlan
Journal:  Blood       Date:  2004-05-11       Impact factor: 22.113

6.  Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV.

Authors:  Wesley C Van Voorhis; Lynn K Barrett; Richard T Eastman; Ryan Alfonso; Kent Dupuis
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

7.  Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat?

Authors:  Hatsadee Appassakij; Paiwon Khuntikij; Marisa Kemapunmanus; Rochana Wutthanarungsan; Khachornsakdi Silpapojakul
Journal:  Transfusion       Date:  2012-11-26       Impact factor: 3.157

8.  Contrasting effects of rabbit and human platelets on chikungunya virus infectivity.

Authors:  M A Chernesky; R P Larke
Journal:  Can J Microbiol       Date:  1977-09       Impact factor: 2.419

9.  Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004.

Authors:  Kibet Sergon; Charles Njuguna; Rosalia Kalani; Victor Ofula; Clayton Onyango; Limbaso S Konongoi; Sheryl Bedno; Heather Burke; Athman M Dumilla; Joseph Konde; M Kariuki Njenga; Rosemary Sang; Robert F Breiman
Journal:  Am J Trop Med Hyg       Date:  2008-02       Impact factor: 2.345

10.  A single mutation in chikungunya virus affects vector specificity and epidemic potential.

Authors:  Konstantin A Tsetsarkin; Dana L Vanlandingham; Charles E McGee; Stephen Higgs
Journal:  PLoS Pathog       Date:  2007-12       Impact factor: 6.823

View more
  10 in total

1.  Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.

Authors:  Dragoslav Domanović; Ines Ushiro-Lumb; Veerle Compernolle; Sergio Brusin; Markus Funk; Pierre Gallian; Jørgen Georgsen; Mart Janssen; Teresa Jimenez-Marco; Folke Knutson; Giancarlo M Liumbruno; Polonca Mali; Giuseppe Marano; Yuyun Maryuningsih; Christoph Niederhauser; Constantina Politis; Simonetta Pupella; Guy Rautmann; Karmin Saadat; Imad Sandid; Ana P Sousa; Stefania Vaglio; Claudio Velati; Nicole Verdun; Miguel Vesga; Paolo Rebulla
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

2.  Effect of inactivating RNA viruses by coupled UVC and UVA LEDs evaluated by a viral surrogate commonly used as a genetic vector.

Authors:  Yun Zhao; Jianfei Dong
Journal:  Biomed Opt Express       Date:  2022-07-28       Impact factor: 3.562

3.  Evaluation of bacterial inactivation in random donor platelets and single-donor apheresis platelets by the INTERCEPT blood system.

Authors:  Raj Nath Makroo; Raman Sardana; Leena Mediratta; Hena Butta; Uday Kumar Thakur; Soma Agrawal; Mohit Chowdhry; Satendra Kumar; Sourit Chokroborty
Journal:  Asian J Transfus Sci       Date:  2018 Jul-Dec

Review 4.  Tropism of the Chikungunya Virus.

Authors:  Giulia Matusali; Francesca Colavita; Licia Bordi; Eleonora Lalle; Giuseppe Ippolito; Maria R Capobianchi; Concetta Castilletti
Journal:  Viruses       Date:  2019-02-20       Impact factor: 5.048

5.  Mitigating the risk of transfusion-transmitted infections with vector-borne agents solely by means of pathogen reduction.

Authors:  Susan L Stramer; Marion C Lanteri; Jaye P Brodsky; Gregory A Foster; David E Krysztof; Jamel A Groves; Rebecca L Townsend; Edward Notari; Sonia Bakkour; Mars Stone; Graham Simmons; Bryan Spencer; Laura Tonnetti; Michael P Busch
Journal:  Transfusion       Date:  2022-06-21       Impact factor: 3.337

6.  Assessment of dengue virus inactivation in random donor platelets using amotosalen and ultraviolet A illumination.

Authors:  Ankit Kumar; Aseem Kumar Tiwari; Satendra Kumar; Ashutosh Biswas; Gurpreet Singh; Kabita Chatterjee; Sourit Chakroborty; Sujatha Sunil
Journal:  Asian J Transfus Sci       Date:  2022-05-26

Review 7.  Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.

Authors:  Marion C Lanteri; Felicia Santa-Maria; Andrew Laughhunn; Yvette A Girard; Marcus Picard-Maureau; Jean-Marc Payrat; Johannes Irsch; Adonis Stassinopoulos; Peter Bringmann
Journal:  Transfusion       Date:  2020-04-24       Impact factor: 3.157

8.  Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions.

Authors:  Sara Castiglia; Katia Mareschi; Luciana Labanca; Graziella Lucania; Marco Leone; Fiorella Sanavio; Laura Castello; Deborah Rustichelli; Elena Signorino; Monica Gunetti; Massimiliano Bergallo; Anna Maria Bordiga; Ivana Ferrero; Franca Fagioli
Journal:  Cytotherapy       Date:  2014-02-12       Impact factor: 5.414

9.  Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation.

Authors:  Steve Kleinman; Adonis Stassinopoulos
Journal:  Transfusion       Date:  2015-08-25       Impact factor: 3.157

10.  Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology.

Authors:  Yvette A Girard; Felicia Santa Maria; Marion C Lanteri
Journal:  Transfusion       Date:  2020-01-20       Impact factor: 3.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.